about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Luisa Salter-Cid joins long­time Bris­tol My­ers col­lab­o­ra­tor Paul Bion­di at Flag­ship's new drug brew­ery

5 years ago
People

George Golumbes­ki signs on at a Eu­ro­pean spe­cial­ist VC firm with $265M to bet on ge­net­ic dis­eases

5 years ago
People
Financing

Prothena col­lects $60M Parkin­son's mile­stone from Roche; As­traZeneca's Pas­cal So­ri­ot faces proxy push­back on pay ...

5 years ago
News Briefing

The in­cu­ba­tor that hatched a Jen­nifer Doud­na CRISPR start­up blue­prints new 'des­ti­na­tion for life sci­ence ...

5 years ago
Startups

Months af­ter emerg­ing from stealth, Nu­va­lent fol­lows up with $135M Se­ries B — backed by some ac­tive play­ers on the ...

5 years ago
Financing

Ahead of Nas­daq de­but, Saurabh Sa­ha pads out the C-suite at Centes­sa, hir­ing a top Dai­ichi Sankyo alum as CMO

5 years ago
People

Per­cep­tive's $310M US/Chi­na play woos new CEO from Eli Lil­ly's top-speed bam­lanivimab team

5 years ago
People

Roger Perl­mut­ter’s new gig, Covid-19 IP dra­ma, Vivek Ra­maswamy's coach on the SPAC train, and more

5 years ago
Weekly

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

5 years ago
R&D
Pharma

Drug pric­ing watch­dog joins the cho­rus of crit­ics on Bio­gen's ad­u­canum­ab: What about charg­ing $2,560 per year?

5 years ago
Pharma

Tak­ing dou­ble Covid-19 hits, Mer­ck writes off $170M for scrapped drug, high­lights $600M in missed sales

5 years ago
R&D

2sev­en­ty: Nick Leschly brings a trio of top ex­ecs with him on top-speed flight from the blue­bird nest

5 years ago
People

'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

5 years ago
People
Startups

Lon­nie Moul­der woos a sea­soned de­vel­op­ment ex­pert from Hill­house­'s US/Chi­na play to helm his start­up

5 years ago
People

Per­son­al­ized elec­tric stim­u­la­tion for epilep­sy, de­pres­sion? Morn­ing­side bets $17.5M on an idea dat­ing back to Ro­man ...

5 years ago
Financing

Stealthy Third Rock start­up poach­es on­col­o­gy ex­ec from No­var­tis — just days af­ter his boss jumped ship

5 years ago
People

A mus­cled up Mod­er­na fi­nal­ly joins the CO­V­AX crew, pledg­ing 500M dos­es for low-in­come coun­tries

5 years ago
Deals
Coronavirus

Qui­et end for flashy up­start, the PD-(L)1 reck­on­ing that was­n't, Big Phar­ma's Covid-19 year, and more

5 years ago
Weekly

Ex­clu­sive: Ohana, Flag­ship's big bet on fer­til­i­ty treat­ments, shuts down and lays off staff af­ter VC pulls the plug

5 years ago
Startups

Lat­est news: Com­mit­tee votes to restart J&J vac­ci­na­tions, check­point gi­ants prep de­fense, un­der­dog vac­cine en­ters the ...

5 years ago
Weekly

Covid-19 roundup: EMA ups Pfiz­er, Mod­er­na vac­cine man­u­fac­tur­ing ca­pa­bil­i­ties amid short­age

5 years ago
Coronavirus

On the heels of $250M launch, Centes­sa barges ahead with an IPO to fu­el its 10-in-1 Medicxi pipeline

5 years ago
Financing

Covid-19 vac­cine halt drags on, an FDA ap­point­ment at long last, the great CRO con­sol­i­da­tion, and more

5 years ago
Weekly

Eli Lil­ly-part­nered biotech taps star in­ves­ti­ga­tor Alan List as CMO — a year af­ter he re­signed from Mof­fitt over ...

5 years ago
People
First page Previous page 51525354555657 Next page Last page
A service from the Financial Times